OGN (NYSE) - Organon & Co

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68622V1061
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey. Web URL: https://www.organon.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for OGN (NYSE) - Organon & Co


Market Cap in USD 5,658m
Sector Healthcare
Industry Drug Manufacturers-General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2021-06-02


Fundamental -1.50
Dividend 4.27
Performance 5y -6.00
Rel. Performance vs Sector -2.71
Analysts 3.20
Fair Price Total Ret. 15.06
Fair Price DCF todo


Growth TTM -22.66%
CAGR 5y -20.99%
CAGR / Mean Drawdown 5y -0.88
Sharpe Ratio TTM -0.80
Alpha vs SP500 TTM -39.07
Beta vs SP500 5y weekly 0.83
CAPM 7.15%
Average Daily Range 2m 2.60%
Reversal Oscillator 16.07
Volatility GJR Garch 1y 39.03%
Price / SMA 50 -16.7%
Price / SMA 200 -24.36%
Current Volume 3237k
Average Volume 20d 3164.1k


Yield TTM 6.45%
Yield on Cost 5y 3.69%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 100.0%